At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 113 enrolled
Drug / intervention
VIR-3434 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of VIR-3434
In Brief
A Phase 1 clinical trial evaluating VIR-3434 and Placebo for Chronic Hepatitis B. Completed, enrolled 113 participants across 24 sites in 7 countries.
Detailed Summary
This is a Phase 1 study in which healthy volunteers and participants with chronic HBV infection will receive VIR-3434 or placebo and will be assessed for safety, tolerability, pharmacokinetics (PK), and antiviral activity (only in participants with chronic HBV infection).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis B
CountriesGermany, Hong Kong, New Zealand, Romania, Singapore, South Korea, United Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
Enrollment StartMay 2020
First PostedJun 2020
Primary CompletionOct 2022
Study CompletionNov 2022
TodayJul 2026
First PostedJun 9, 2020
Enrollment StartMay 26, 2020
Primary CompletionOct 24, 2022
Study CompletionNov 25, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.1 years ago
Interventions
VIR-3434biological
VIR-3434 given by subcutaneous injection or intravenous infusion.
Placeboother
Sterile normal saline (0.9% NaCl) given by subcutaneous injection or intravenous infusion.